C-反应蛋白与非小细胞肺癌免疫治疗预后的研究进展

doi:10.3760/cma.j.cn371439-20240805-00133

国际肿瘤学杂志 ›› 2024, Vol. 51 ›› Issue (12): 785-788.doi: 10.3760/cma.j.cn371439-20240805-00133

C-反应蛋白与非小细胞肺癌免疫治疗预后的研究进展

伏彩红¹, 辛元春², 顾峰¹, 吴玉强¹, 李慧慧¹, 马琴¹, 刘喜婷¹(), 杨磊¹

¹甘肃省肿瘤医院呼吸肿瘤内科，兰州 730000
²甘肃省肿瘤医院放疗科，兰州 730000

收稿日期:2024-08-05 修回日期:2024-08-30 出版日期:2024-12-08 发布日期:2025-01-07
通讯作者: 刘喜婷 E-mail:liuxiting@163.com
基金资助:
甘肃省卫生健康行业科研计划(GSWSKY2022-53)

Research progress in C-reactive protein and the prognosis of immunotherapy for non-small cell lung cancer

Fu Caihong¹, Xin Yuanchun², Gu Feng¹, Wu Yuqiang¹, Li Huihui¹, Ma Qin¹, Liu Xiting¹(), Yang Lei¹

¹Department of Respiratory Oncology， Gansu Provincial Cancer Hospital， Lanzhou 730000， China
²Department of Radiotherapy， Gansu Provincial Cancer Hospital， Lanzhou 730000， China

Received:2024-08-05 Revised:2024-08-30 Online:2024-12-08 Published:2025-01-07
Contact: Liu Xiting E-mail:liuxiting@163.com
Supported by:
Gansu Provincial Health Industry Scientific Research Project(GSWSKY2022-53)

摘要/Abstract

摘要：

免疫治疗已成为驱动基因阴性晚期非小细胞肺癌（NSCLC）的一线标准治疗方案，但并非所有的患者均能从免疫治疗中获益，甚至可发生严重的不良反应，确定免疫治疗临床反应预测因子至关重要。多项研究表明，基线C-反应蛋白（CRP）升高或治疗过程中CRP持续升高可能提示患者预后不良，并且高CRP可能与不良反应有一定的相关性，CRP在NSCLC免疫治疗过程中的动态变化可能成为患者预后的一个重要预测因素。

关键词: 癌，非小细胞肺, C反应蛋白质, 免疫疗法, 预后

Abstract:

Immunotherapy has become the first-line standard treatment option for driver gene-negative advanced non-small cell lung cancer （NSCLC）. But not all patients can benefit from immunotherapy， and can even have serious adverse reactions. It is crucial to identify the predictors of clinical response to immunotherapy. Several studies have shown that elevated baseline C-reactive protein （CRP） or persistent elevation of CRP during the treatment process may indicate a poorer prognosis for patients，and high CRP may be correlated with adverse reactions. Attention to the dynamic changes of CRP during immunotherapy for NSCLC may become an important predictor of prognosis.

Key words: Carcinoma， non-small cell lung, C-reactive protein, Immunotherapy, Prognosis

伏彩红, 辛元春, 顾峰, 吴玉强, 李慧慧, 马琴, 刘喜婷, 杨磊. C-反应蛋白与非小细胞肺癌免疫治疗预后的研究进展[J]. 国际肿瘤学杂志, 2024, 51(12): 785-788.

Fu Caihong, Xin Yuanchun, Gu Feng, Wu Yuqiang, Li Huihui, Ma Qin, Liu Xiting, Yang Lei. Research progress in C-reactive protein and the prognosis of immunotherapy for non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(12): 785-788.

参考文献 22

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183): 1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. pmid: 30955977
[3]	Naqash AR, Stroud CRG, Butt MU, et al. Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database[J]. Acta Oncol, 2018, 57(6): 867-872. DOI: 10.1080/0284186X.2017.1415460. pmid: 29241410
[4]	Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)[J]. BMC Cancer, 2020, 20(1): 1185. DOI: 10.1186/s12885-020-07690-8.
[5]	Peng L, Wang Y, Liu F, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors[J]. Cancer Immunology Immunotherapy, 2020, 69(9): 1813-1822. DOI: 10.1007/s00262-020-02585-w.
[6]	Baracos VE, Martin L, Korc M, et al. Cancer-associated cachexia[J]. Nat Rev Dis Primers, 2018, 4: 17105. DOI: 10.1038/nrdp.2017.105. pmid: 29345251
[7]	Li W, Luo X, Liu Z, et al. Prognostic value of C-reactive protein levels in patients with bone neoplasms: a meta-analysis[J]. PLoS One, 2018, 13(4): e0195769. DOI: 10.1371/journal.pone.0195769.
[8]	Laino AS, Woods D, Vassallo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition[J]. J Immunother Cancer, 2020, 8(1): e000842. DOI: 10.1136/jitc-2020-000842.
[9]	Li J, Duran MA, Dhanota N, et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis[J]. Cancer Discov, 2021, 11(5): 1212-1227. DOI: 10.1158/2159-8290.CD-20-0387.
[10]	Boison D, Yegutkin GG. Adenosine metabolism: emerging concepts for cancer therapy[J]. Cancer Cell, 2019, 36(6): 582-596. DOI: 10.1016/j.ccell.2019.10.007. pmid: 31821783
[11]	Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014, 515(7528): 568-571. DOI: 10.1038/nature13954.
[12]	Iivanainen S, Ahvonen J, Knuuttila A, et al. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors[J]. ESMO Open, 2019, 4(4): e000531. DOI: 10.1136/esmoopen-2019-000531.
[13]	Lindenmann J, Fink-Neuboeck N, Taucher V, et al. Prediction of postoperative clinical outcomes in resected stage Ⅰ non-small cell lung cancer focusing on the preoperative glasgow prognostic score[J]. Cancers(Basel), 2020, 12(1): 152. DOI: 10.3390/cancers12010152.
[14]	Koukourakis MI, Kambouromiti G, Pitsiava D, et al. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication[J]. Inflammation, 2009, 32(3): 169-175. DOI: 10.1007/s10753-009-9116-4. pmid: 19373547
[15]	Oya Y, Yoshida T, Kuroda H, et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer[J]. Oncotarget, 2017, 8(61): 103117-103128. DOI: 10.18632/oncotarget.21602.
[16]	Riedl JM, Barth DA, Brueckl WM, et al. C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study[J]. Cancers(Basel), 2020, 12(8): 2319. DOI: 10.3390/cancers12082319.
[17]	Inomata M, Hirai T, Seto Z, et al. Clinical parameters for predicting the survival in patients with squamous and non-squamous-cell NSCLC receiving PD-1 inhibitor therapy[J]. Pathol Oncol Res, 2020, 26(1): 327-333. DOI: 10.1007/s12253-018-0473-x. pmid: 30232703
[18]	Zheng X, Zhang L, Wu L, et al. Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study[J]. BMC Cancer, 2023, 23(1): 1244. DOI: 10.1186/s12885-023-11737-x.
[19]	Schiwitza A, Schildhaus HU, Zwerger B, et al. Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer[J]. Immunotherapy, 2019, 11(9): 769-782. DOI: 10.2217/imt-2019-0039. pmid: 31120392
[20]	Suazo-Zepeda E, Bokern M, Vinke PC, et al. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis[J]. Cancer Immunol Immunother, 2021, 70(11): 3069-3080. DOI: 10.1007/s00262-021-02996-3. pmid: 34195862
[21]	Nakanishi Y, Masuda T, Yamaguchi K, et al. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer[J]. Respir Investig, 2019, 57(5): 451-459. DOI: 10.1016/j.resinv.2019.05.002. pmid: 31248832
[22]	Fukihara J, Sakamoto K, Koyama J, et al. Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors[J]. Clin Lung Cancer, 2019, 20(6): 442-450, e4. DOI: 10.1016/j.cllc.2019.07.006. pmid: 31446020

C-反应蛋白与非小细胞肺癌免疫治疗预后的研究进展

Research progress in C-reactive protein and the prognosis of immunotherapy for non-small cell lung cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 22

相关文章 15

编辑推荐

Metrics

本文评价

[1]	袁胜芳, 任婕, 林卫佳, 姬泽萱, 张长洪, 王布. EGFR共突变状态对晚期肺腺癌患者预后的价值研究[J]. 国际肿瘤学杂志, 2024, 51(9): 556-562.
[2]	黄波, 汪鹏. 血清sCD163、IFN-γ联合TGF-β1对NSCLC患者放疗后发生放射性肺炎的早期预测价值[J]. 国际肿瘤学杂志, 2024, 51(9): 563-568.
[3]	王清北, 朱林, 吴正国. NSCLC肺内叶段淋巴结转移规律及全胸腔镜肺叶切除术中淋巴结清扫方式的选择[J]. 国际肿瘤学杂志, 2024, 51(9): 569-577.
[4]	伍杨, 李甜, 张润兵, 史婷婷, 高春, 郑晓凤, 张久聪. 胃癌及食管胃结合部癌免疫及靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 595-600.
[5]	倪国英, 黄骞, 梁洪享, 杨志勇, 丁颖丽. 晚期非小细胞肺癌患者血清miR-499、miR-362水平变化及与预后的关系分析[J]. 国际肿瘤学杂志, 2024, 51(8): 487-492.
[6]	吕俊, 熊昊, 郑燕秋, 董礼. 非小细胞肺癌患者放疗后肺部侵袭性真菌病发生危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(8): 493-497.
[7]	孟珂心, 陆海军. 口腔菌群：口腔鳞状细胞癌诊断和预后的生物标志物[J]. 国际肿瘤学杂志, 2024, 51(8): 515-519.
[8]	刘昊, 靳二梅, 丁红娟, 金磊. 非小细胞肺癌患者血清HMGB2和HMGB3水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(7): 448-452.
[9]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[10]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[15]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.